JAK inhibitors in GCA? We have a phase 3 trial in giant cell arteritis back on the opening day plenary stage. The SELECT-GCA study, looking at upadacitinib in GCA, was scheduled to anchor the #ACR24 opening plenary for a reason - it is highly notable and badly needed.… https://t.co/aJ3uao1wD7 https://t.co/6ao2OoODHg

Highlights in axSpA Dr. Marina Magrey discusses highlights in axSpA from the first day at #ACR24 https://t.co/LvvmzlXWw7 https://t.co/thf9MiMo32

ANCA Vasculitis "Eye": Can rituximab help? Dr. Janet Pope discusses abstract 0726 at #ACR24 https://t.co/KzYcmjon8D https://t.co/KDIi1vJE4P

RA Treatment Adherence: Is decision making really shared? Dr. Jonathan Kay interviews Dr. Cécile Gaujoux-Viala about abstract 0360 at #ACR24. https://t.co/KwXHutfQko https://t.co/bCVM3JrFEz

Treat-to-Target Improves Fertility in Women with RA Dr. Richard Conway discusses abstract 1647, presented at #ACR24 https://t.co/vC0CA0lN4M https://t.co/Dfo7iBYwcU

GLP-1 Agonists Show Promise in Slowing Kidney Disease in Lupus Nephritis Glucagon-like peptide-1 receptor agonists (GLP-1Ra) have transformed the treatment landscape for type 2 diabetes and obesity. #ACR24 https://t.co/6QqEH8X2VJ https://t.co/Ch2i9zZYii

ORAL Surveillance - Is Statin Use the Problem/Solution? The findings from ORAL Surveillance Study have been a dominant conversation at #ACR24, with the seminal findings and subsequent analyses a target of debate. https://t.co/Nn9KSL4dlv https://t.co/gHPwK35eEd

#ACR24: What Exactly do JAKs and TYKs Do? Let me start by confessing something embarrassing: the immune system is just too complex for me to understand. I suspect the onslaught of new drugs with new mechanisms at ACR 2024 may have left many of you feeling similarly.… https://t.co/HkhZJBxDdO https://t.co/xYeSpHS2dD

Addressing CV Risk in RA: Are we doing enough? The increased risk of cardiovascular disease in patients with rheumatoid arthritis has long been known (1). #ACR24 https://t.co/dajYuK8rpd https://t.co/2Ds3OZEjUX

Apremilast Benefits and Risks in PsA Dr. Akhil Sood discusses abstracts 1466, 2583, 0598 and 2640 discussing the use of apremilast in PsA, presented at #ACR24. https://t.co/SSEeR9Xt9B https://t.co/cUeSUQoRsO

#ACR24 BEST Abstracts from Day 2 Here’s a collection of some of the best abstracts presented on day 2 of ACR 2024 as selected by the RheumNow faculty. https://t.co/9qiPhemEPl https://t.co/uGQEiCcfah

#ACR24 - Day 2 Report Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024. https://t.co/TEWW0mDyl8 https://t.co/mZuqayonPN